NASDAQ:OPNTOpiant Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Opiant Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.06 -0.01 (-0.11 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$8.86Now: $9.06▼$9.1650-Day Range$8.83MA: $9.22▼$9.5452-Week Range$8.05Now: $9.06▼$18.23Volume37,302 shsAverage Volume41,187 shsMarket Capitalization$38.58 millionP/E Ratio5.27Dividend YieldN/ABeta0.76 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOpiant Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.00, Opiant Pharmaceuticals has a potential upside of 364.1% from its current price of $9.05.Amount of Analyst CoverageOpiant Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesOpiant Pharmaceuticals has received 260 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOpiant Pharmaceuticals has received 281 “underperform” votes. (Add your “underperform” vote.)Community SentimentOpiant Pharmaceuticals has received 51.94% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote “Outperform” if you believe OPNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOpiant Pharmaceuticals does not currently pay a dividend.Dividend GrowthOpiant Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Opiant Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,540.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 28.02% of the stock of Opiant Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 25.10% of the stock of Opiant Pharmaceuticals is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Opiant Pharmaceuticals are expected to grow in the coming year, from ($0.75) to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opiant Pharmaceuticals is 5.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 17.46.Price to Earnings Ratio vs. SectorThe P/E ratio of Opiant Pharmaceuticals is 5.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.26.Price to Book Value per Share RatioOpiant Pharmaceuticals has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.16 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Metal mining Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPNT Previous Symbol CUSIPN/A CIK1108924 Webwww.opiant.com Phone310-598-5410Debt Debt-to-Equity RatioN/A Current Ratio8.65 Quick Ratio8.65Price-To-Earnings Trailing P/E Ratio5.27 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40.52 million Price / Sales0.95 Cash Flow$0.28 per share Price / Cash Flow32.27 Book Value$8.41 per share Price / Book1.08Profitability EPS (Most Recent Fiscal Year)$0.20 Net Income$11.59 million Net Margins25.32% Return on Equity-2.45% Return on Assets-2.04%Miscellaneous Employees16 Outstanding Shares4,258,000Market Cap$38.58 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $9.06 -0.01 (-0.11 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive OPNT News and Ratings via Email Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions How has Opiant Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OPNT stock has decreased by 16.5% and is now trading at $9.06. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Opiant Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opiant Pharmaceuticals. When is Opiant Pharmaceuticals' next earnings date? Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Opiant Pharmaceuticals. How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its quarterly earnings results on Thursday, August, 6th. The technology company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.26. The technology company earned $6.31 million during the quarter, compared to analyst estimates of $6.47 million. Opiant Pharmaceuticals had a negative return on equity of 2.45% and a net margin of 25.32%. View Opiant Pharmaceuticals' earnings history. What price target have analysts set for OPNT? 1 brokers have issued 1-year price objectives for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 363.6% from the stock's current price. View analysts' price targets for Opiant Pharmaceuticals. Has Opiant Pharmaceuticals been receiving favorable news coverage? Media coverage about OPNT stock has trended somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned headlines about the technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Opiant Pharmaceuticals. Are investors shorting Opiant Pharmaceuticals? Opiant Pharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 11,100 shares, a decline of 26.0% from the June 15th total of 15,000 shares. Based on an average trading volume of 69,400 shares, the short-interest ratio is currently 0.2 days. Currently, 0.3% of the company's stock are sold short. View Opiant Pharmaceuticals' Short Interest. Who are some of Opiant Pharmaceuticals' key competitors? Some companies that are related to Opiant Pharmaceuticals include Rubicon Minerals (RBYCF), Fission Uranium (FCUUF), Amerigo Resources (ARREF), Mountain Province Diamonds (MPVDF), Lexaria Bioscience (LXRP), Atlatsa Resources (ATLRF), Santa Fe Gold (SFEG), US Gold (USAU), Dakota Territory Resource (DTRC), Bullfrog Gold (BFGC), Pacific Booker Minerals (PBMLF), Silver Bull Resources (SVBL), Avalon Advanced Materials (AVLNF), Quaterra Resources (QTRRF) and Westwater Resources (WWR). View all competitors. What other stocks do shareholders of Opiant Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Synchrony Financial (SYF), Vodafone Group (VOD), Corbus Pharmaceuticals (CRBP), Cyberark Software (CYBR), AT&T (T), Agenus (AGEN), Aurinia Pharmaceuticals (AUPH) and Cronos Group (CRON). Who are Opiant Pharmaceuticals' key executives? Opiant Pharmaceuticals' management team includes the following people: Dr. Roger Crystal, CEO & Director (Age 43)Mr. David D. O'Toole, Chief Financial Officer (Age 60)Dr. Phil Skolnick, Chief Scientific Officer (Age 72)Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)Mr. Quan Vu, VP of Corp. Devel. What is Opiant Pharmaceuticals' stock symbol? Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT." Who are Opiant Pharmaceuticals' major shareholders? Opiant Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perritt Capital Management Inc. (0.69%) and Advisor Group Holdings Inc. (0.08%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick and Roger Crystal. View institutional ownership trends for Opiant Pharmaceuticals. Which major investors are selling Opiant Pharmaceuticals stock? OPNT stock was sold by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc., and Advisor Group Holdings Inc.. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Michael Sinclair, and Phil Skolnick. View insider buying and selling activity for Opiant Pharmaceuticals. How do I buy shares of Opiant Pharmaceuticals? Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Opiant Pharmaceuticals' stock price today? One share of OPNT stock can currently be purchased for approximately $9.06. How big of a company is Opiant Pharmaceuticals? Opiant Pharmaceuticals has a market capitalization of $38.58 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe. What is Opiant Pharmaceuticals' official website? The official website for Opiant Pharmaceuticals is www.opiant.com. How can I contact Opiant Pharmaceuticals? Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at investor.rela[email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
